Crowdonomics
All companies
CHOOSE YOUR HORIZON logo

CHOOSE YOUR HORIZON

Operating

Choose Your Horizon Inc.

Healthcare · Austin, TX · Founded 2018

Transforming lives with proven at home psychedelic therapy

Post-money valuation
$22.3M
As of Oct 2024 · from Choose Your Horizon Common Stock 2 · pre-money + amount raised, not a traded price
Total raised
$1,091,324
Across 2 rounds since 2023
Latest share price
$0.68
Choose Your Horizon Common Stock 2 offering price

Financials

FY2021–FY2025 · from SEC filings · hover any figure for its source
$3K
$3K
2021
$113K
−$385K
2022
$1.2M
−$1.3M
2023
$1.1M
−$1.4M
2024
$3.1M
−$771K
2025
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2021
FY2022
FY2023
FY2024
FY2025
Income statement
Revenue
$2,585
$113,337
$1,153,913
$1,122,581
$3,133,581
Cost of goods sold
$0
$98,180
$377,711
$352,789
$910,967
Gross margin
100%
13%
67%
69%
71%
Net income
$2,570
-$385,429
-$1,301,365
-$1,402,702
-$770,734
Taxes paid
$0
$0
$677
$0
$0
Balance sheet
Cash
$4,107
$474,611
$117,328
$14,061
$42,490
Accounts receivable
$0
$0
$269,733
$163,109
$166,061
Total assets
$4,107
$477,536
$389,986
$186,285
$211,495
Short-term debt
$26
$0
$73,901
$416,119
$744,761
Long-term debt
$0
$0
$1,483,000
$1,684,000
$2,233,406
Total liabilities
$26
$0
$1,556,901
$2,100,119
$2,978,167
Other
Headcount
6
6
7
12

Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited; no pill means the filing didn’t state one. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.

Valuation over rounds

Post-money = pre-money + amount raised · caps marked
$16.0M
post-money
$22.3M
post-money
Reg CF Offering (2023)
Choose Your Horizon Common Stock 2

A dashed amber step is a SAFE/note valuation cap — a conversion ceiling agreed for that instrument, not a priced valuation of the company. Steps are not comparable across bases.

Fundraising history

Choose Your Horizon Common Stock 2ClosedReg CF · Common Equity · via StartEngine
Raised $193K / $3.8MInvestors 102Post-money $22.3M
Reg CF Offering (2023)ClosedReg CF · Common Equity · via StartEngine
Raised $898.3K / $5MInvestors 584Post-money $16M

Team

8 people
Mark HollandFounder
Founder & CEO

Mark, a serial entrepreneur in consumer health, is CEO of Choose Your Horizon, a telehealth company offering affordable Ketamine Therapy in 23 states for treatment-resistant anxiety, depression, and more. He previously built a $50M nutraceutical business, which he sold to a Fortune 500 company, and has chaired YPO’s Sustainable Business Network.

Rob LeeFounder
Co-founder & COO

Co-founder & COO Rob Lee has 15+ years of experience in executive operations and business development, contributing to two successful consumer health exits worth over $250M. He holds a master’s in international business (2015) and a degree in business finance (2012).

Dr. Daniel Montville
Chief Medical Officer

Chief Medical Officer at Choose Your HorizonDaniel Montville, MD brings a compassionate and evidence-based approach to his role as Chief Medical Officer at Choose Your Horizon. With a commitment to guiding individuals through the complexities of mental health, Dr. Montville integrates personalized care with the latest clinical advancements to support patients in achieving meaningful, lasting wellness. Dr. Montville earned his Bachelor of Science from the University of Wisconsin-Madison and his Doctor of Medicine from the Chicago Medical School. He completed his psychiatry residency at the prestigious Mayo Clinic in Rochester, Minnesota, where he served as Chief Resident. His areas of expertise include mood disorders, substance use disorders, perinatal psychiatry, and emergency psychiatry. Dr. Montville, a proud Minnesota native, is deeply committed to providing accessible, person-centered mental health care. When he's not working, he enjoys exploring the Midwest, diving into binge-worthy TV miniseries, and cherishing time with family and friends.At Choose Your Horizon, Dr. Montville's leadership and clinical vision drive innovative mental health solutions, including ketamine-assisted therapy and cutting-edge treatments for depression, anxiety, PTSD, and addiction. His dedication to empowering patients with the tools and resources to take charge of their mental health is central to the mission of Choose Your Horizon.

Robert Lee
COO, Director and principal accounting officer
Danielle McFarlin
Lead Integration Specialist & Patient Care Coordinator

Danielle McFarlin is a TEDx speaker, author, and rape crisis advocate who has been guiding transformative experiences with psychedelic medicines since 2010, using Shamanism as the foundation of her practice. She aims to be a beacon of hope for those who feel their lives are beyond repair.

Dominique Louis PMHNP
Lead Psychiatric NP

Dominique Louis is a double-published, board-certified psychiatric nurse practitioner with over a decade of experience in ketamine therapy. Her background spans critical care, nurse education, community health, outpatient addiction, partial residential, and inpatient care for adolescent and adult mental health populations.

Dr. Habir Singh
Medical Advisor

Dr. Harbir Singh is a Board Certified Emergency Medicine Physician with extensive experience in patient care, both in and out of the hospital. As CEO of Kyle ER & Hospital near Austin, TX, he provides high-quality, concierge care at lower costs. Dr. Singh is dedicated to addressing major healthcare challenges and has significant experience with ketamine in clinical settings.

Dr. Stephanie Coleman
Medical Advisor

Dr. Stephanie Coleman is a board-certified physician trained at Upstate Medical University, with a residency at Boston Medical Center & a fellowship at Beth Israel Deaconess Harvard Hospital. She is a member of the Psychedelic Medicine Association, the American Society of Ketamine Physicians, & a graduate of several psychedelic practitioner programs, including CIIS.

Names and titles as disclosed on SEC Form C, StartEngine. Bios and photos come from the platform campaign page and may be out of date.

Reg CF annual-report compliance

Not required3+ reports filed & assets ≤ $10M

Filed 3 of 3 annual reports (FY2023–FY2025)

584 investors
holder-count proxy

Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.

  • Form C-ARJan 29, 20260001997555-26-000001
    EDGAR
  • Form C-ARJun 18, 20250001997555-25-000004
    EDGAR
  • Form C-UMar 4, 20250001665160-25-000372
    EDGAR
  • Form C/ADec 16, 20240001665160-24-001818
    EDGAR
  • Form COct 30, 20240001665160-24-001508
    EDGAR
  • Form C-AR/AApr 19, 20240001665160-24-000393
    EDGAR
  • Form C-UApr 17, 20240001665160-24-000374
    EDGAR
  • Form C-ARApr 16, 20240001665160-24-000369
    EDGAR
Source: ManualCIK 0001997555DEShare price $0.68

About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.